A new peer-reviewed paper published in Frontiers in Global Women’s Health maps the current state of femtech innovation across diagnostics, wearables, and AI – and proposes a strategic framework for ensuring that technological progress translates into equitable clinical impact.
The paper, authored by a team at Amsterdam-based YON E Health, synthesizes recent advances including CRISPR-based point-of-care diagnostics, menstrual blood biomarkers for endometriosis, intravaginal biosensors, and AI-enabled predictive models – then examines why technical maturity doesn’t always reach the populations that need it most. It identifies six categories of barriers: systemic (gender bias in research funding), structural (fragmented health systems), cultural (stigma around menstruation and menopause), data (underrepresentation in datasets driving algorithmic bias), regulatory (outdated frameworks for hybrid digital-medical products), and access (affordability, connectivity, and digital literacy gaps in low- and middle-income countries).
The proposed four-pillar framework for building a more equitable femtech ecosystem includes mandating inclusive multi-site validation and bias-aware regulation, building ethical and privacy-preserving data infrastructure, embedding culturally responsive co-design with the women who will use these tools, and fostering equitable funding mechanisms that go beyond the less than 0.5% of healthcare venture capital currently allocated to women’s health.
The paper notes that while innovations like menstrual fluid diagnostics and AI symptom clustering show strong technical promise, most lack prospective validation across diverse populations – meaning tools developed in high-resource settings may not perform equitably when deployed elsewhere.
